PL358381A1 - Przeciwciała monoklonalne skierowane wobec ludzkiego receptora LDL, ich wytwarzanie i zastosowanie - Google Patents

Przeciwciała monoklonalne skierowane wobec ludzkiego receptora LDL, ich wytwarzanie i zastosowanie

Info

Publication number
PL358381A1
PL358381A1 PL01358381A PL35838101A PL358381A1 PL 358381 A1 PL358381 A1 PL 358381A1 PL 01358381 A PL01358381 A PL 01358381A PL 35838101 A PL35838101 A PL 35838101A PL 358381 A1 PL358381 A1 PL 358381A1
Authority
PL
Poland
Prior art keywords
production
monoclonal antibodies
ldl receptor
human ldl
human
Prior art date
Application number
PL01358381A
Other languages
English (en)
Other versions
PL206041B1 (pl
Inventor
Nachum Yonah
Dany Suissa
Ilana Belzer
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL358381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL13502500A external-priority patent/IL135025A0/xx
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of PL358381A1 publication Critical patent/PL358381A1/pl
Publication of PL206041B1 publication Critical patent/PL206041B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL358381A 2000-03-13 2001-03-08 Przeciwciało monoklonalne, przeciwciało chimerowe, całkowicie humanizowane przeciwciało, przeciwciało anty-anty-ID albo jego fragment oraz ich zastosowanie, klony hybrydoma, sposób wykrywania i/albo analizy ilościowej ludzkiego LDLR, sposób oczyszczania oraz sposób hamowania in vitro replikacji wirusa zapalenia wątroby typu C PL206041B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13502500A IL135025A0 (en) 2000-03-13 2000-03-13 Monoclonal antibodies to the human ldl receptor, their production and use
IL13921700A IL139217A0 (en) 2000-03-13 2000-10-23 Monoclonal antibodies to the human ldl receptor, their production and use
PCT/IL2001/000216 WO2001068710A1 (en) 2000-03-13 2001-03-08 Monoclonal antibodies to the human ldl receptor, their production and use

Publications (2)

Publication Number Publication Date
PL358381A1 true PL358381A1 (pl) 2004-08-09
PL206041B1 PL206041B1 (pl) 2010-06-30

Family

ID=26323933

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358381A PL206041B1 (pl) 2000-03-13 2001-03-08 Przeciwciało monoklonalne, przeciwciało chimerowe, całkowicie humanizowane przeciwciało, przeciwciało anty-anty-ID albo jego fragment oraz ich zastosowanie, klony hybrydoma, sposób wykrywania i/albo analizy ilościowej ludzkiego LDLR, sposób oczyszczania oraz sposób hamowania in vitro replikacji wirusa zapalenia wątroby typu C

Country Status (32)

Country Link
US (1) US6849720B2 (pl)
EP (1) EP1263790B1 (pl)
JP (1) JP4768193B2 (pl)
KR (1) KR100882081B1 (pl)
CN (1) CN1418225B (pl)
AR (1) AR028518A1 (pl)
AT (1) ATE362490T1 (pl)
AU (2) AU4100201A (pl)
BG (1) BG65762B1 (pl)
BR (1) BR0109164A (pl)
CA (1) CA2402593C (pl)
CY (1) CY1108020T1 (pl)
CZ (1) CZ20023098A3 (pl)
DE (1) DE60128452T2 (pl)
DK (1) DK1263790T3 (pl)
EA (1) EA007494B1 (pl)
EE (1) EE200200517A (pl)
ES (1) ES2282238T3 (pl)
HR (1) HRP20020704B1 (pl)
HU (1) HU226194B1 (pl)
IL (2) IL139217A0 (pl)
MX (1) MXPA02009091A (pl)
NO (1) NO330904B1 (pl)
NZ (1) NZ520944A (pl)
PL (1) PL206041B1 (pl)
PT (1) PT1263790E (pl)
RS (1) RS51406B (pl)
SI (1) SI1263790T1 (pl)
SK (1) SK287348B6 (pl)
UA (1) UA78489C2 (pl)
WO (1) WO2001068710A1 (pl)
ZA (1) ZA200206654B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
CA2525517C (en) 2003-06-19 2016-05-31 Applied Research Systems Ars Holding N.V. Use of prion conversion modulating agents
FR2889532B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
FR2889533B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
JP2009526991A (ja) * 2006-02-17 2009-07-23 パオロ・ラ・コッラ 増殖性疾患及び／又はコンホメーション病の診断方法
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
IL188628A0 (en) * 2008-01-07 2008-12-29 Yeda Res & Dev Use of soluble ldl-r for viral hepatitis
GB0922377D0 (en) * 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
US20130129676A1 (en) 2010-05-25 2013-05-23 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
CN103111270B (zh) * 2013-02-26 2015-06-10 王业富 一种乙型肝炎抗原蛋白的吸附材料及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法

Also Published As

Publication number Publication date
AU4100201A (en) 2001-09-24
BG65762B1 (bg) 2009-10-30
EA200200974A1 (ru) 2003-02-27
US20030186343A1 (en) 2003-10-02
DK1263790T3 (da) 2007-07-02
CA2402593C (en) 2012-07-03
US6849720B2 (en) 2005-02-01
RS51406B (sr) 2011-02-28
DE60128452T2 (de) 2007-09-13
KR20020089384A (ko) 2002-11-29
PL206041B1 (pl) 2010-06-30
MXPA02009091A (es) 2005-06-20
ATE362490T1 (de) 2007-06-15
DE60128452D1 (de) 2007-06-28
AU2001241002B8 (en) 2006-05-04
BG107063A (bg) 2003-05-30
ES2282238T3 (es) 2007-10-16
IL139217A0 (en) 2001-11-25
EA007494B1 (ru) 2006-10-27
BR0109164A (pt) 2002-11-26
CZ20023098A3 (cs) 2003-02-12
IL151713A0 (en) 2003-04-10
UA78489C2 (en) 2007-04-10
KR100882081B1 (ko) 2009-02-10
NO20024223L (no) 2002-10-24
CY1108020T1 (el) 2013-09-04
NO20024223D0 (no) 2002-09-04
PT1263790E (pt) 2007-06-01
ZA200206654B (en) 2003-10-20
AU2001241002B2 (en) 2006-04-06
EE200200517A (et) 2004-02-16
HUP0300142A3 (en) 2005-07-28
NZ520944A (en) 2004-04-30
HU226194B1 (hu) 2008-06-30
WO2001068710A1 (en) 2001-09-20
EP1263790A1 (en) 2002-12-11
YU68602A (sh) 2006-03-03
HRP20020704B1 (en) 2011-01-31
SI1263790T1 (sl) 2007-10-31
CN1418225A (zh) 2003-05-14
NO330904B1 (no) 2011-08-15
HK1055750A1 (en) 2004-01-21
SK287348B6 (sk) 2010-08-09
EP1263790B1 (en) 2007-05-16
CN1418225B (zh) 2012-04-18
HUP0300142A2 (hu) 2003-06-28
SK13122002A3 (sk) 2003-04-01
CA2402593A1 (en) 2001-09-20
HRP20020704A2 (en) 2004-12-31
JP4768193B2 (ja) 2011-09-07
JP2004506603A (ja) 2004-03-04
AR028518A1 (es) 2003-05-14

Similar Documents

Publication Publication Date Title
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
MXPA03009390A (es) Anticuerpos para integrina vla-1.
IL166244A0 (en) Super humanized antibodies
AU8390301A (en) Antibodies to human MCP-1
AU4835001A (en) Antibodies to human cd154
GB0029360D0 (en) Humanised antibodies and uses thereof
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
EP1418234A4 (en) HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST OXIDIZED LDL RECEPTORS AND THEIR MEDICAL USE
IL139217A0 (en) Monoclonal antibodies to the human ldl receptor, their production and use
AU5441000A (en) Human monoclonal antibody
AU2002325164A1 (en) Receptor, the use thereof, and mouse antibodies
IL135025A0 (en) Monoclonal antibodies to the human ldl receptor, their production and use
EP1278538A4 (en) ANTIBODIES BINDING TO CD18 AND INHIBITING STENOSE-RELATED DISORDERS
AU2001281099A1 (en) Production of human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.
GB0024673D0 (en) Therapeutic antibodies
GB0008160D0 (en) Monoclonal antibodies
GB0003359D0 (en) Monoclonal antibodies